Cancer Immunology Immunotherapy,
Год журнала:
2024,
Номер
73(8)
Опубликована: Июнь 4, 2024
Abstract
Immunotherapy
is
one
of
the
most
promising
anti-cancer
treatment.
It
involves
activating
host's
own
immune
system
to
eliminate
cancer
cells.
Activation
cGAS-STING
pathway
therapeutic
approach
for
immunotherapy.
However,
in
human
clinical
trials,
targeting
results
insufficient
or
unsustainable
anti-tumor
response.
To
enhance
its
effectiveness,
combination
with
other
therapies
seems
essential
achieve
synergistic
systemic
The
aim
this
study
was
evaluate
whether
STING
agonist-cGAMP
anti-vascular
RGD-(KLAKLAK)
2
peptide
a
better
response
poorly
immunogenic
tumors
various
protein
and
α
v
β
3
integrin
status.
Combination
therapy
inhibited
growth
murine
breast
carcinoma
more
effectively
than
melanoma.
In
melanoma,
administration
agonist
alone
sufficient
obtain
satisfactory
effect.
both
tumor
models
we
have
noted
stimulation
innate
following
cGAMP
combination.
largest
population
cells
infiltrating
TME
after
were
activated
NK
Increased
infiltration
cytotoxic
CD8
+
T
lymphocytes
within
only
observed
melanoma
tumors.
they
also
expressed
“exhaustion”
PD-1
receptor.
contrast,
each
caused
drop
number
obtained
indicate
an
additional
benefit
from
combining
agent.
effect
depends
on
type
tumor,
status
microenvironment
expression
specific
proteins
such
as
family
integrin.
Chemical Reviews,
Год журнала:
2023,
Номер
123(13), С. 8297 - 8346
Опубликована: Июнь 15, 2023
Omics
technologies
have
rapidly
evolved
with
the
unprecedented
potential
to
shape
precision
medicine.
Novel
omics
approaches
are
imperative
toallow
rapid
and
accurate
data
collection
integration
clinical
information
enable
a
new
era
of
healthcare.
In
this
comprehensive
review,
we
highlight
utility
Raman
spectroscopy
(RS)
as
an
emerging
technology
for
clinically
relevant
applications
using
significant
samples
models.
We
discuss
use
RS
both
label-free
approach
probing
intrinsic
metabolites
biological
materials,
labeled
where
signal
from
reporters
conjugated
nanoparticles
(NPs)
serve
indirect
measure
tracking
protein
biomarkers
Frontiers in Nutrition,
Год журнала:
2023,
Номер
10
Опубликована: Фев. 16, 2023
Metabolic
reprogramming
is
one
of
fourteen
hallmarks
tumor
cells,
among
which
aerobic
glycolysis,
often
known
as
the
“Warburg
effect,”
essential
to
fast
proliferation
and
aggressive
metastasis
cells.
Lactate,
on
other
hand,
a
ubiquitous
molecule
in
microenvironment
(TME),
generated
primarily
by
cells
undergoing
glycolysis.
To
prevent
intracellular
acidification,
malignant
remove
lactate
along
with
H
+
,
yet
acidification
TME
inevitable.
Not
only
does
highly
concentrated
within
serve
substrate
supply
energy
but
it
also
works
signal
activate
multiple
pathways
that
enhance
invasion,
intratumoral
angiogenesis,
well
immune
escape.
In
this
review,
we
aim
discuss
latest
findings
metabolism
particularly
capacity
extracellular
influence
microenvironment.
addition,
examine
current
treatment
techniques
employing
existing
medications
target
interfere
generation
transport
cancer
therapy.
New
research
shows
targeting
metabolism,
lactate-regulated
action
are
viable
therapy
strategies.
Clinically,
multimodal
therapies
are
adopted
worldwide
for
the
management
of
cancer,
which
continues
to
be
a
leading
cause
death.
In
recent
years,
immunotherapy
has
firmly
established
itself
as
new
paradigm
in
cancer
care
that
activates
body's
immune
defense
cope
with
cancer.
Immunotherapy
resulted
significant
breakthroughs
treatment
stubborn
tumors,
dramatically
improving
clinical
outcome
patients.
Multiple
forms
immunotherapy,
including
checkpoint
inhibitors
(ICIs),
adoptive
cell
therapy
and
vaccines,
have
become
widely
available.
However,
effectiveness
these
immunotherapies
is
not
much
satisfying.
Many
patients
do
respond
disease
recurrence
appears
unavoidable
because
rapidly
evolving
resistance.
Moreover,
can
give
rise
severe
off-target
immune-related
adverse
events.
Strategies
remove
hindrances
mainly
focus
on
development
combinatorial
or
exploitation
novel
immunotherapeutic
mediations.
Nanomaterials
carrying
anticancer
agents
target
site
considered
practical
approaches
treatment.
Nanomedicine
combined
offers
possibility
potentiate
systemic
antitumor
immunity
facilitate
selective
cytotoxicity
against
cells
an
effective
safe
manner.
A
myriad
nano-enabled
currently
under
investigation.
Owing
gaps
between
preclinical
studies,
nano-immunotherapy
faces
multiple
challenges,
biosafety
nanomaterials
trial
design.
this
review,
we
provide
overview
summarize
evidence
indicating
how
nanomedicine-based
increase
efficacy
immunotherapies.
We
also
discuss
key
challenges
emerged
era
nanotechnology-based
immunotherapy.
Taken
together,
combination
drawing
increasing
attention,
it
anticipated
will
achieve
desired
success
therapy.
Cancer
immunotherapy
is
a
promising
antitumor
approach,
whereas
nontherapeutic
side
effects,
tumor
microenvironment
(TME)
intricacy,
and
low
immunogenicity
limit
its
therapeutic
efficacy.
In
recent
years,
combination
with
other
therapies
has
been
proven
to
considerably
increase
However,
achieving
codelivery
of
the
drugs
site
remains
major
challenge.
Stimulus-responsive
nanodelivery
systems
show
controlled
drug
delivery
precise
release.
Polysaccharides,
family
potential
biomaterials,
are
widely
used
in
development
stimulus-responsive
nanomedicines
due
their
unique
physicochemical
properties,
biocompatibility,
modifiability.
Here,
activity
polysaccharides
several
combined
strategies
(e.g.,
chemotherapy,
photodynamic
therapy,
or
photothermal
therapy)
summarized.
More
importantly,
progress
polysaccharide-based
for
cancer
discussed,
focus
on
construction
nanomedicine,
targeted
delivery,
release,
enhanced
effects.
Finally,
limitations
application
prospects
this
new
field
discussed.
Cell Communication and Signaling,
Год журнала:
2024,
Номер
22(1)
Опубликована: Март 12, 2024
Abstract
The
programmed
cell
death
1
(PD-1)
signaling
pathway,
a
key
player
in
immune
checkpoint
regulation,
has
become
focal
point
cancer
immunotherapy.
In
the
context
of
cancer,
upregulated
PD-L1
on
tumor
cells
can
result
T
exhaustion
and
evasion,
fostering
progression.
advent
PD-1/PD-L1
inhibitor
demonstrated
clinical
success
by
unleashing
from
exhaustion.
Nevertheless,
challenges
such
as
resistance
adverse
effects
have
spurred
exploration
innovative
strategies,
with
bispecific
antibodies
(BsAbs)
emerging
promising
frontier.
BsAbs
offer
multifaceted
approach
to
immunotherapy
simultaneously
targeting
other
regulatory
molecules.
We
focus
recent
advancements
therapy
particular
emphasis
development
potential
BsAbs,
especially
solid
tumors.
Various
BsAb
products
PD-1
are
discussed,
highlighting
their
unique
mechanisms
action
therapeutic
potential.
Noteworthy
examples
include
anti-TGFβ
×
PD-L1,
anti-CD47
anti-VEGF
anti-4-1BB
anti-LAG-3
anti-PD-1
CTLA-4
BsAbs.
Besides,
we
summarize
ongoing
studies
evaluating
efficacy
safety
these
agents.
By
unraveling
intricacies
microenvironment
harnessing
synergistic
anti-PD-1/PD-L1
there
exists
elevate
precision
immunotherapy,
ultimately
enabling
personalized
treatment
strategies
tailored
individual
patient
profiles.
ACS Nano,
Год журнала:
2024,
Номер
18(8), С. 6445 - 6462
Опубликована: Фев. 15, 2024
Tumor-associated
macrophages
(TAMs)
are
closely
related
to
the
progression
of
glioblastoma
multiform
(GBM)
and
its
development
therapeutic
resistance
conventional
chemotherapy.
TAM-targeted
therapy
combined
with
chemotherapy
has
emerged
as
a
promising
strategy
combat
GBM.
However,
presence
blood–brain
barrier
(BBB)
severely
limits
efficacy.
Meanwhile,
lack
ability
distinguish
different
targeted
cells
also
poses
challenge
for
precise
therapy.
Herein,
we
propose
cathepsin
B
(CTSB)-responsive
programmed
brain-targeted
delivery
system
(D&R-HM-MCA)
simultaneous
GBM-targeted
delivery.
D&R-HM-MCA
could
cross
BBB
via
low
density
lipoprotein
receptor-associated
protein
1
(LRP1)-mediated
transcytosis.
Upon
reaching
GBM
site,
outer
angiopep-2
modification
be
detached
from
cleavage
CTSB-responsive
peptide,
which
circumvent
abluminal
LRP1-mediated
efflux.
The
exposed
p-aminophenyl-α-d-mannopyranoside
(MAN)
further
recognize
glucose
transporter-1
(GLUT1)
on
macrophage
mannose
receptor
(MMR)
TAMs.
achieve
chemotherapeutic
killing
simultaneously
induce
TAM
polarization
anti-inflammatory
M2
phenotype
pro-inflammatory
M1
phenotype,
thus
resensitizing
response
improving
anti-GBM
immune
response.
This
not
only
can
improve
brain
efficiency,
but
enable
combination
chemo-immunotherapy
against
effectiveness
this
may
provide
thinking
designing
more
functional
systems
effective
regimens.
Biology,
Год журнала:
2024,
Номер
13(5), С. 307 - 307
Опубликована: Апрель 28, 2024
Cancer
immune
evasion
represents
a
leading
hallmark
of
cancer,
posing
significant
obstacle
to
the
development
successful
anticancer
therapies.
However,
landscape
cancer
treatment
has
significantly
evolved,
transitioning
into
era
immunotherapy
from
conventional
methods
such
as
surgical
resection,
radiotherapy,
chemotherapy,
and
targeted
drug
therapy.
Immunotherapy
emerged
pivotal
component
in
treatment,
harnessing
body’s
system
combat
offering
improved
prognostic
outcomes
for
numerous
patients.
The
remarkable
success
spurred
efforts
enhance
clinical
efficacy
existing
agents
strategies.
Several
immunotherapeutic
approaches
have
received
approval
treatments,
while
others
are
currently
preclinical
trials.
This
review
explores
recent
progress
unraveling
mechanisms
evaluates
effectiveness
diverse
strategies,
including
vaccines,
adoptive
cell
therapy,
antibody-based
treatments.
It
encompasses
both
established
treatments
those
under
investigation,
providing
comprehensive
overview
through
immunological
approaches.
Additionally,
article
emphasizes
current
developments,
limitations,
challenges
immunotherapy.
Furthermore,
by
integrating
analyses
resistance
exploring
combination
strategies
personalized
approaches,
it
offers
valuable
insights
crucial
novel
